Mark James Litton - 27 Jan 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Chief Executive Officer, Director
Signature
/s/ Glenna Mileson, Attorney-in-Fact on behalf of Mark Litton
Issuer symbol
ATHA
Transactions as of
27 Jan 2023
Net transactions value
+$1,814
Form type
4
Filing time
31 Jan 2023, 18:33:50 UTC
Previous filing
24 Jun 2022
Next filing
08 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATHA Common Stock Award $1,814 +662 +0.51% $2.74 129,217 18 Nov 2022 Direct F1, F2, F3
holding ATHA Common Stock 6,563 27 Jan 2023 By Irrevocable Trust of OSL F4
holding ATHA Common Stock 6,563 27 Jan 2023 By Irrevocable Trust of SWL F5
holding ATHA Common Stock 6,563 27 Jan 2023 By Irrevocable Trust of WGL F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +425,000 $0.000000 425,000 27 Jan 2023 Common Stock 425,000 $4.11 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2022 through November 18, 2022. This transaction is also exempt under Rule 16b-3(c).
F2 The Purchase Period ended November 18, 2022 and is the sole Purchase Period in the Offering Period (as defined in the ESPP) that began May 18, 2022.
F3 In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2022.
F4 Reflects Common Stock held by Irrevocable Trust of OSL held for the benefit of Dr. Litton's children.
F5 Reflects Common Stock held by Irrevocable Trust of SWL held for the benefit of Dr. Litton's children.
F6 Reflects Common Stock held by Irrevocable Trust of WGL held for the benefit of Dr. Litton's children.
F7 One thirty-sixth (1/36th) of the shares subject to the option will vest on February 27, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter.